Angiodynamics reports fiscal year 2024 second quarter financial results; revises fiscal year 2024 guidance

Latham, n.y.--(business wire)--angiodynamics, inc. (nasdaq: ango), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving quality of life for patients, today announced financial results for the second quarter of fiscal year 2024, which ended november 30, 2023. “today, we are announcing meaningful steps in our strategic transformation. we have initiated a restructuring of our.
ANGO Ratings Summary
ANGO Quant Ranking